Share this article

Asahi Kasei company Zoll has signed an exclusive distribution agreement with BrainCool for the BrainCool System/IQool System and the IQool System Pads in the US and major European markets.

The companies also plan to work together to expand distribution to selected Asian markets.

The agreement broadens Zoll’s range of temperature management solutions, encompassing both intravascular technology and surface options.

Branded as the IQool System in the US, the BrainCool System is an advanced surface temperature management system with gel-free and adhesive-free pads.

This system is intended to maintain fever control and manage patient temperature in critical care settings.

The IQool System has programmable protocol settings and acute temperature control, as well as an advanced user interface.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Zoll Circulation president Christopher Barnabas said: “Expanding Zoll’s temperature management offering to include a high-quality surface option supports our mission to improve patient outcomes and help save lives.

“With our Thermogard XPand Thermogard HQ products – the world’s only intravascular temperature management technology – and BrainCool’s IQool System, we now offer a unique combination of solutions that deliver high-quality patient care while recognising hospitals’ evolving protocols and increased nursing workload.”

In May this year, Zoll secured approval from the US Food and Drug Administration for its remedē system for conditional use with magnetic resonance imaging.

The implantable transvenous phrenic nerve stimulator is intended for treating patients who experience moderate to severe central sleep apnea.